Altimmune Inc (ALT)
7.02
-0.05
(-0.71%)
USD |
NASDAQ |
May 02, 12:33
Altimmune Cash from Operations (TTM): -75.81M for Dec. 31, 2023
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | -75.81M |
| September 30, 2023 | -76.58M |
| June 30, 2023 | -71.15M |
| March 31, 2023 | -68.47M |
| December 31, 2022 | -62.59M |
| September 30, 2022 | -67.25M |
| June 30, 2022 | -69.97M |
| March 31, 2022 | -72.20M |
| December 31, 2021 | -78.24M |
| September 30, 2021 | -69.55M |
| June 30, 2021 | -61.28M |
| March 31, 2021 | -49.53M |
| December 31, 2020 | -34.31M |
| September 30, 2020 | -23.03M |
| June 30, 2020 | -15.95M |
| March 31, 2020 | -11.84M |
| December 31, 2019 | -9.602M |
| September 30, 2019 | -12.76M |
| June 30, 2019 | -11.35M |
| March 31, 2019 | -7.943M |
| December 31, 2018 | -9.389M |
| September 30, 2018 | -9.040M |
| June 30, 2018 | -12.28M |
| March 31, 2018 | -20.43M |
| December 31, 2017 | -20.21M |
| Date | Value |
|---|---|
| September 30, 2017 | -16.90M |
| June 30, 2017 | -14.54M |
| March 31, 2017 | -8.341M |
| December 31, 2016 | -6.353M |
| September 30, 2016 | -6.689M |
| June 30, 2016 | -6.123M |
| March 31, 2016 | -1.858M |
| December 31, 2015 | -3.216M |
| September 30, 2015 | -4.910M |
| June 30, 2015 | -5.707M |
| March 31, 2015 | -8.893M |
| December 31, 2014 | -8.474M |
| September 30, 2014 | -11.21M |
| June 30, 2014 | -9.761M |
| March 31, 2014 | -9.723M |
| December 31, 2013 | -7.168M |
| September 30, 2013 | -3.057M |
| June 30, 2013 | -0.6455M |
| March 31, 2013 | -2.854M |
| December 31, 2012 | -2.323M |
| September 30, 2012 | -0.983M |
| June 30, 2012 | -6.336M |
| March 31, 2012 | -4.930M |
| December 31, 2011 | -7.809M |
| September 30, 2011 | -13.72M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (TTM) Range, Past 5 Years
-78.24M
Minimum
Dec 2021
-9.602M
Maximum
Dec 2019
-49.55M
Average
-62.59M
Median
Dec 2022
Cash from Operations (TTM) Benchmarks
| Eli Lilly and Co | 3.676B |
| Amgen Inc | 8.471B |
| Pfizer Inc | 8.70B |
| Viking Therapeutics Inc | -54.87M |
| Precision BioSciences Inc | -84.11M |